Quantcast

Latest Hepatocellular carcinoma Stories

2014-05-20 23:18:15

In its May 2014 survey, polyDNA found that 36% of respondents wanted to know what complications can arise from a hepatitis B infection. polyDNA reviews the literature, and recommends Gene-Eden-VIR and Novirin, which have a formula proven to reduce viral symptoms in two post-marketing clinical studies. Rochester, NY (PRWEB) May 20, 2014 In polyDNA’s latest survey, 36% of participants wanted to know what complications can arise from a hepatitis B infection. The answer is that a long-term,...

2014-05-20 04:21:04

GENEVA, May 20, 2014 /PRNewswire/ -- The International Federation of Pharmaceutical Manufacturers and Associations [http://www.ifpma.org ] (IFPMA) has published today a new report and recommendations on Hepatitis, encouraging a comprehensive approach to fighting this silent epidemic. Titled "Towards a Sustainable, Intersectoral Approach to Viral Hepatitis [http://www.ifpma.org/fileadmin/content/Publication/2014/IFPMA_Viral_Hepatitis_May2014.pdf ] ", the report is meant to...

2014-05-19 23:03:14

Advocacy groups warn that threat of viral hepatitis is “creeping up” on city’s vulnerable populations PHILADELPHIA, Pa. (PRWEB) May 19, 2014 A chorus of voices supporting increased access to viral hepatitis testing for Philadelphia residents echoed through a recent city council meeting, as advocacy groups joined forces to deliver a powerful message. More than 55 members of Hep B United Philadelphia, led by the Hepatitis B Foundation, and the Hepatitis C Allies of Philadelphia...

2014-05-16 08:26:24

Abstract Presents a Retrospective Analysis of the Company's 701 Patient HEAT Study and Compelling Data Showing Enhanced Efficacy When Radiofrequency Ablation is Combined with ThermoDox and When Heating Time of the RFA Procedure is Greater Than 45 Minutes LAWRENCEVILLE, N.J., May 16, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that an abstract on its Phase III HEAT Study of ThermoDox, the Company's proprietary...

2014-05-14 16:29:06

WHIPPANY, N.J., May 14, 2014 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. announced today that data from its oncology portfolio, including NEXAVAR(®) (sorafenib) tablets, Xofigo(®) (radium Ra 223 dichloride) injection and Stivarga(®) (regorafenib) tablets, will be presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), May 30 - June 3, in Chicago, IL (USA). Bayer will also present data from its late stage clinical pipeline, investigating...

2014-05-08 08:32:55

Company on Track to Launch Phase III OPTIMA Study in Second Quarter LAWRENCEVILLE, N.J., May 8, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the first quarter ended March 31, 2014 and provided an update on its development program for ThermoDox®, the Company's proprietary heat-activated liposomal encapsulation of doxorubicin. ThermoDox is being evaluated in a Phase III program for primary liver...

2014-05-08 08:32:52

DOYLESTOWN, Pa., May 8, 2014 /PRNewswire/ -- Novira Therapeutics, Inc., a privately held biopharmaceutical company developing novel therapies for curative treatment of chronic hepatitis B virus (HBV) infection, today announced that it initiated a Phase 1a clinical study of NVR-1221. The Phase 1a clinical study is designed to assess the pharmacokinetic profile and dose-related safety and tolerability of NVR-1221 in healthy volunteers. "We are thrilled to begin the clinical development...

2014-05-07 12:30:32

Preclinical studies show CF102 helps liver regenerate cells and repair itself following surgery or other injury PETACH TIKVA, Israel, May 7, 2014 /PRNewswire/ -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today it has been issued European Patent No. 2227234 for its invention titled, "Method for inducing hepatocyte proliferation and uses...

2014-05-07 12:29:49

Personalized Drug Treatment Will Emerge for HCC with the Approval of a Novel Biomarker-Targeted Agent, According to Findings from Decision Resources Group BURLINGTON, Mass., May 7, 2014 /PRNewswire/ -- Decision Resources Group finds that the treatment landscape of hepatocellular carcinoma (HCC) will change dramatically through 2023 as new therapies gain approval and launch for second-line treatment of advanced HCC following disease progression/intolerance to first-line Nexavar (Bayer...

2014-05-01 23:02:50

The Hepatitis B Foundation will visit Philadelphia City Council to ask city leaders to support increased testing for the viral liver diseases hepatitis B and C in Philadelphia’s at-risk populations. Philadelphia (PRWEB) May 01, 2014 Date: Thursday, May 8, 2014 Time: 10 a.m. Location: Philadelphia City Council, 494 N Broad Street, Philadelphia, Pa. 19107 Details: The Hepatitis B Foundation will visit Philadelphia City Council to ask city leaders to support increased testing for the...


Latest Hepatocellular carcinoma Reference Libraries

Hepatitis B
2013-02-25 09:11:23

Image Caption: This electron micrograph reveals the presence of hepatitis-B virus HBV "Dane particles", or virions. Credit: CDC/Wikipedia Hepatitis B: What Is It? Hepatitis simply means a swelling or inflammation of the liver. The type hepatitis that a person contracts (there are 5 common forms) affects their long-term prognosis. The most common and most severe of these different types of liver infection is Hepatitis B, which is caused by the hepatitis B virus (HBV). It is typically...

45_36624a455e3cd9a4152b7670308f0ffa
2011-01-20 19:14:56

Hepatitis B virus, HBV, is a part of the Hepadnaviridae family of viruses. HBV can lead to cirrhosis and hepatocellular carcinoma and has been linked to pancreatic cancer. It is classified as a species of the Orthohepadnavirus. Similar viruses have been found worldwide in great apes and monkeys. There a few different genotypes and they all differ by at least 8% of the sequence and have distinct geographical distributions and this has been associated with anthropological history. Type A is...

0_9255b919f71eff1fd4202c1dbb1795d2
2011-01-12 15:49:29

Hepadnaviruses can cause liver infections in humans and animals. The two recognized genera are Genus Orthohepadnavirus and Genus Avihepadnavirus. It has a small genome of partially double-stranded, partially single stranded circular DNA. It is a group 7 virus that uses an RNA intermediate during replication. Most people who come into contact with the virus are able to clear the infection alone although some cannot and usually progress to fulminant hepatitis. It can cause sever liver...

More Articles (3 articles) »
Word of the Day
bellycheer
  • Good cheer; viands.
  • To revel; to feast.
The word 'bellycheer' may come from 'belle cheer', "good cheer".
Related